Trezise succeeds Leveridge as new chair of ELRIG
8 Apr 2025
ELRIG, the not-for-profit organisation for the drug discovery community, has appointed Dr Del Trezise as its new board chair.
He succeeds Melanie Leveridge, whose four-year term ends this year.
Trezise boasts more than 30 years in academia, biotech, and biopharma settings and currently holds lnon-executive and advisory roles at Sartorius, Axol Bioscience, Semarion, and Refeyn.
As co-founder of the European arm of Essen BioScience, he developed industrial-scale, live-cell imaging technology for drug discovery and previously held senior director positions at GlaxoSmithKline R&D.
He has been an active supporter of ELRIG since 2013, variously serving as scientific programme chair, early career professionals work group leader and head of the innovation work group before joining the ELRIG Board in 2017.
His first major responsibility in his new position will be to host Drug Discovery 2025 in Liverpool, UK, from 21–22 October.
Trezise paid tribute to his predecessor Leveridge saying: “Mel has been an outstanding leader, guiding ELRIG through significant growth, including navigating the COVID-19 pandemic, expanding the professional team, and embedding meaningful EDI principles.
“I’m excited to build on this foundation by further strengthening collaboration between our community partners through our world-class conferences and events.
